TAXUS Liberte Post Approval Study: A U.S. Post-Approval Study of the TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Paclitaxel (Primary) ; Aspirin; Prasugrel
- Indications Coronary artery disease; Coronary artery restenosis; Coronary stent thrombosis
- Focus Therapeutic Use
- Acronyms TL-PAS
- Sponsors Boston Scientific Corporation
- 20 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 22 Apr 2015 Trial design has been changed from interventional to observational as reported by ClinicalTrials.gov record.
- 12 Apr 2015 Planned End Date changed from 1 Mar 2017 to 1 Aug 2015 as reported by ClinicalTrials.gov record.